Abstract
The human population is infested with dermatological diseases. For example, at a global scale, 95% of people are infected with the Herpes Simplex Virus (HSV) and 90% of people contract the Human Papillomavirus (HPV) in their lifetime. Yet, while the healthcare law literature is visibly scaling, the research relating to the law and economic systems controlling treatment for ubiquitous dermatological disease is non-existent. First, this Article explains the biological understructure for common dermatological diseases. Second, this Article introduces a novel dataset sampling dermatology patents and providing market models, legal claims analysis, and valuation guidelines. Third, this paper discusses future dermatological technologies and regulatory access issues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
